910297-51-7
Chemical Structure
N-Deshydroxyethyl Dasatinib
Synonym(s): N-Deshydroxyethyl BMS-354825
- CAS 番号: 910297-51-7
- Formula:C20H22ClN7OS
- Molecular Weight:443.95
IUPAC Name: N-(2-chloro-6-methylphenyl)-2-((2-methyl-6-(piperazin-1-yl)pyrimidin-4-yl)amino)thiazole-5-carboxamide
InChIKey: DOBZFFWLHXORTB-UHFFFAOYSA-N
SMILES: O=C(C1=CN=C(NC2=NC(C)=NC(N3CCNCC3)=C2)S1)NC4=C(C)C=CC=C4Cl
Biological Activity: N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825) is a metabolite of Dasatinib, Dasatinib is a multi-kinase inhibitor that potently inhibits Bcr-Abl, Src family and platelet-derived growth factor receptor kinases. N-Deshydroxyethyl Dasatinib can be used in cancer and immune disease research[1][2].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
N-Deshydroxyethyl Dasatinib | 97.19% | N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825) is a metabolite of Dasatinib, Dasatinib is a multi-kinase inhibitor that potently inhibits Bcr-Abl, Src family and platelet-derived growth factor receptor kinases. N-Deshydroxyethyl Dasatinib can be used in cancer and immune disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Deshydroxyethyl Dasatinib (Standard) | ≥98% | N-Deshydroxyethyl Dasatinib (Standard) is the analytical standard of N-Deshydroxyethyl Dasatinib. This product is intended for research and analytical applications. N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825) is a metabolite of Dasatinib, Dasatinib is a multi-kinase inhibitor that potently inhibits Bcr-Abl, Src family and platelet-derived growth factor receptor kinases. N-Deshydroxyethyl Dasatinib can be used in cancer and immune disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Deshydroxyethyl Dasatinib-d8 | N-Deshydroxyethyl Dasatinib-d8 is the deuterium labeled N-Deshydroxyethyl Dasatinib. N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.86
HY-111857Dasatinib carbaldehyde -
Similarity Score 0.84
HY-10181RDasatinib (Standard) -
Similarity Score 0.84
HY-10181ADasatinib hydrochloride -
Similarity Score 0.84
HY-10181BDasatinib monohydrate -
Similarity Score 0.83
HY-183103PDD-87 -
Similarity Score 0.83
HY-175193N-Deshydroxyethyl Dasatinib-C3-NH2 -
Similarity Score 0.83
HY-131669Dasatinib metabolite M6 -
Similarity Score 0.83
HY-176462Gly-Dasatinib -
Similarity Score 0.82
HY-133794RDasatinib N-oxide (Standard) -
Explore the MedChemAI to find more analogs
References
- [1]. Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017 Aug;108(8):1657-1666. [Content Brief]
- [2]. Thappali SR, et al. Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study. Arzneimittelforschung. 2012 Dec;62(12):624-30. [Content Brief]
